A phase I/II trial of vandetanib for patients with recurrent malignant glioma

Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM).

(2017) E. C. Quant et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

(2013) Paul Martin et al.   Drugs in research & development

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

(2008) Michael Michael et al.   INVESTIGATIONAL NEW DRUGS

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY